Cited by 222Immunotherapy and Immune ResponsesVirus-based gene therapy researchBacterial Cancer Therapy

The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.

Viral Vector-Based Therapeutic Cancer Vaccines

Open access

Larocca, Cecilia, Schlom, Jeffrey·2011·The Cancer Journal

DOI 10.1097/ppo.0b013e3182325e63PMC PMC3207353

Open this paper in CoChat — free account

Abstract

Most viruses are naturally immunogenic and can be engineered to express tumor antigen transgenes. Moreover, many types of recombinant viruses have been shown to infect professional antigen-presenting cells, specifically dendritic cells, and express their transgenes. This enhanced presentation of tumor antigens to the immune system has led to an increase in the frequency and avidity of cytotoxic T lymphocytes that target tumor cells expressing the tumor antigen(s) encoded in the vaccine vector. Logistically, recombinant viruses can be produced, administered, and quality controlled more easily compared with other immunotherapy strategies. The intrinsic properties of each virus have distinct advantages and disadvantages, which can determine their applicability in a particular therapeutic setting. The disadvantage of some vectors is the development of host-induced neutralizing antibodies to the vector itself, thus limiting its continued use. The "off-the-shelf" nature of viral vaccine platforms renders them exceptionally suitable for multicenter randomized trials. This review described and discussed the strategies used and results using viral-based vaccines, with emphasis on phases II and III clinical trials. Future directions will involve the evaluation of viral-based vaccines in the adjuvant and neoadjuvant settings, in patients with low burden metastatic disease, and in combination with other forms of therapy including immunotherapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1097/ppo.0b013e3182325e63

Cites

85 of 85 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Trends in Long-Term Survival Following Liver Resection for Hepatic Colorectal Metastases
Choti, M. A., Sitzmann, J. V., Tiburi, M. F., Sumetchotimetha, W., Rangsin, R., Schulick, R. D., Lillemoe, K. D., Yeo, C. J., & Cameron, J. L. (2002) · Annals of Surgery · doi:10.1097/00000658-200206000-00002 · Cited by 1,456
Effect of Surgical Margin Status on Survival and Site of Recurrence After Hepatic Resection for Colorectal Metastases
Pawlik, T. M., Scoggins, C. R., Zorzi, D., Abdalla, E. K., Andrès, A., Eng, C., Curley, S. A., Loyer, E. M., Muratore, A., Mentha, G., et al. (2005) · Annals of Surgery · doi:10.1097/01.sla.0000160703.75808.7d · Cited by 1,103
Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
Kantoff, P. W., Schuetz, T. J., Blumenstein, B. A., Glodé, L. M., Bilhartz, D. L., Wyand, M. S., Manson, K. H., Panicali, D., Laus, R., Schlom, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.0597 · Cited by 994
Self-citation
Survival after Hepatic Resection for Metastatic Colorectal Cancer: Trends in Outcomes for 1,600 Patients during Two Decades at a Single Institution
House, M. G., Ito, H., Gönen, M., Fong, Y., Allen, P. J., DeMatteo, R. P., Brennan, M. F., Blumgart, L. H., Jarnagin, W. R., & D'Angelica, M. I. (2010) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2009.12.040 · Cited by 517
Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety.
Moss, B. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11341 · Cited by 515
Generation of Human Cytotoxic T Cells Specific for Human Carcinoembryonic Antigen Epitopes From Patients Immunized With Recombinant Vaccinia-CEA Vaccine
Tsang, K.-Y., Zaremba, S., Nieroda, C. A., Zhu, M., Hamilton, J. M., & Schlom, J. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.13.982 · Cited by 498
Self-citation
Combination of p53 Cancer Vaccine with Chemotherapy in Patients with Extensive Stage Small Cell Lung Cancer
Antonia, S. J., Mirza, N., Fricke, I., Chiappori, A., Thompson, P., Williams, N., Bepler, G., Simon, G., Janssen, W., Lee, J.-H., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2013 · Cited by 444
Combining a Recombinant Cancer Vaccine with Standard Definitive Radiotherapy in Patients with Localized Prostate Cancer
Gulley, J. L., Arlen, P. M., Bastian, A., Morin, S., Marté, J. L., Beetham, P. K., Tsang, K.-Y., Yokokawa, J., Hodge, J. W., Ménard, C. M., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2062 · Cited by 370
Self-citation
Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: A phase III-study from the German CONKO-study group
Pelzer, U., Schwaner, I., Stieler, J., Adler, M., Seraphin, J., Dörken, B., Riess, H. B., & Oettle, H. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.04.011 · Cited by 369
Phase I Study in Advanced Cancer Patients of a Diversified Prime-and-Boost Vaccination Protocol Using Recombinant Vaccinia Virus and Recombinant Nonreplicating Avipox Virus to Elicit Anti–Carcinoembryonic Antigen Immune Responses
Marshall, J. L., Hoyer, R. J., Toomey, M. A., Faraguna, K., Chang, P., Richmond, E. S., Pedicano, J. E., Gehan, E. A., Peck, R. A., Arlen, P. M., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.23.3964 · Cited by 356
Self-citation
The Genome of Fowlpox Virus
Afonso, C. L., Tulman, E. R., Lu, Z., Zsak, L., Kutish, G. F., & Rock, D. L. (2000) · Journal of Virology · doi:10.1128/jvi.74.8.3815-3831.2000 · Cited by 323
Phase I Study of Sequential Vaccinations With Fowlpox-CEA(6D)-TRICOM Alone and Sequentially With Vaccinia-CEA(6D)-TRICOM, With and Without Granulocyte-Macrophage Colony-Stimulating Factor, in Patients With Carcinoembryonic Antigen–Expressing Carcinomas
Marshall, J. L., Gulley, J. L., Arlen, P. M., Beetham, P. K., Tsang, K.-Y., Slack, R. S., Hodge, J. W., DOREN, S., Grosenbach, D. W., Hwang, J. J., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2005.10.206 · Cited by 298
Self-citation
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer
Gulley, J. L., Arlen, P. M., Madan, R. A., Tsang, K.-Y., Pazdur, M. P., Skarupa, L., Jones, J. L., Poole, D. J., Higgins, J. P., Hodge, J. W., et al. (2009) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-009-0782-8 · Cited by 296
Self-citation
A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer.
Eder, J. P., Kantoff, P. W., Röper, K., Xu, G., Bubley, G. J., Boyden, J., Gritz, L. R., Mazzara, G. P., Oh, W. K., Arlen, P. M., et al. (2000) · PubMed · Cited by 294
Self-citation
A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer.
Arlen, P. M., Gulley, J. L., Parker, C., Skarupa, L., Pazdur, M. P., Panicali, D., Beetham, P. K., Tsang, K. Y., Grosenbach, D. W., Feldman, J. L., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2059 · Cited by 287
Self-citation
Vaccinia virus vaccines: Past, present and future
Jacobs, B. L., Langland, J., Kibler, K. V., Denzler, K. L., White, S. D., Holechek, S., Wong, S., Huynh, T. P., & Baskin, C. R. (2009) · Antiviral Research · doi:10.1016/j.antiviral.2009.06.006 · Cited by 279
Vaccinia virus morphogenesis and dissemination
Roberts, K. L., & Smith, G. L. (2008) · Trends in Microbiology · doi:10.1016/j.tim.2008.07.009 · Cited by 278
Pilot Study of Vaccination with Recombinant CEA-MUC-1-TRICOM Poxviral-Based Vaccines in Patients with Metastatic Carcinoma
Gulley, J. L., Arlen, P. M., Tsang, K.-Y., Yokokawa, J., Palena, C., Poole, D. J., Remondo, C., Cereda, V., Jones, J. L., Pazdur, M. P., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0126 · Cited by 228
Self-citation
Antitumor Activity and Immune Responses Induced by a Recombinant Carcinoembryonic Antigen-Vaccinia Virus Vaccine
Kantor, J. A., Irvine, K. R., Abrams, S. I., Kaufman, H. L., Dipietro, J., & Schlom, J. (1992) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/84.14.1084 · Cited by 210
Self-citation
A Phase II Study of Tg4010 (Mva-Muc1-Il2) in Association with Chemotherapy in Patients with Stage III/IV Non-small Cell Lung Cancer
Ramlau, R., Quoix, É., Rolski, J., Pless, M., Léna, H., Lévy, E., Krzakowski, M. J., Hess, D., Tartour, É., Chenard, M., et al. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31817c6b4f · Cited by 209
Vaccination of Metastatic Renal Cancer Patients with MVA-5T4: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
Amato, R. J., Hawkins, R. E., Kaufman, H. L., Thompson, J. A., Tomczak, P., Szczylik, C. A., McDonald, M., Eastty, S., Shingler, W. H., de Belin, J., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2082 · Cited by 199
Vaccinia Vectors as Candidate Vaccines: The Development of Modified Vaccinia Virus Ankara for Antigen Delivery
Sutter, G., & Staib, C. (2003) · Current Drug Targets - Infectious Disorders · doi:10.2174/1568005033481123 · Cited by 191
The Genome of Canarypox Virus
Tulman, E. R., Afonso, C. L., Lu, Z., Zsak, L., Kutish, G. F., & Rock, D. L. (2003) · Journal of Virology · doi:10.1128/jvi.78.1.353-366.2004 · Cited by 190
Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus.
Kass, E. S., Schlom, J., Thompson, J., Guadagni, F., Graziano, P., & Greiner, J. W. (1999) · PubMed · Cited by 176
Self-citation
Measles Virus for Cancer Therapy
Russell, S. J., & Peng, K.-W. (2008) · Current topics in microbiology and immunology · doi:10.1007/978-3-540-70617-5_11 · Cited by 172
The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma.
von Mehren, M., Arlen, P. M., Gulley, J. L., Rogatko, A., Cooper, H. S., Meropol, N. J., Alpaugh, R. K., Davey, M., McLaughlin, S. B., Beard, M., et al. (2001) · PubMed · Cited by 170
Self-citation
Vaccination of Colorectal Cancer Patients with Modified Vaccinia Ankara Delivering the Tumor Antigen 5T4 (TroVax) Induces Immune Responses which Correlate with Disease Control: A Phase I/II Trial
Harrop, R., Connolly, N. B., Redchenko, I., Valle, J. W., Saunders, M. P., Ryan, M. G., Myers, K. A., Drury, N. L., Kingsman, S. M., Hawkins, R. E., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2732 · Cited by 166
Unexpected Association between Induction of Immunity to the Universal Tumor Antigen CYP1B1 and Response to Next Therapy
Gribben, J. G., Ryan, D. P., Boyajian, R. N., Urban, R. G., Hedley, M. L., Beach, K. J., Nealon, P., Matulonis, U. A., Campos, S. M., Gilligan, T. D., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2111 · Cited by 165
Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas.
von Mehren, M., Arlen, P. M., Tsang, K. Y., Rogatko, A., Meropol, N. J., Cooper, H. S., Davey, M. P., McLaughlin, S. B., Schlom, J., & Weiner, L. M. (2000) · PubMed · Cited by 156
Self-citation
Analysis of Overall Survival in Patients with Nonmetastatic Castration-Resistant Prostate Cancer Treated with Vaccine, Nilutamide, and Combination Therapy
Madan, R. A., Gulley, J. L., Schlom, J., Steinberg, S. M., Liewehr, D. J., Dahut, W. L., & Arlen, P. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5048 · Cited by 150
Self-citation
Multiple Costimulatory Modalities Enhance CTL Avidity
Hodge, J. W., Chakraborty, M., Kudo‐Saito, C., Garnett‐Benson, C., & Schlom, J. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.10.5994 · Cited by 138
Self-citation
Recombinant Vaccinia Virus Encoding Human MUC1 and IL2 as Immunotherapy in Patients With Breast Cancer
Scholl, S., Balloul, J., Goc, G. L., Bizouarne, N., Schatz, C., Kiény, M. P., von Mensdorff‐Pouilly, S., Vincent‐Salomon, A., Deneux, L., Tartour, É., et al. (2000) · Journal of Immunotherapy · doi:10.1097/00002371-200009000-00007 · Cited by 129
Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant.
Kass, E. S., Panicali, D., Mazzara, G. P., Schlom, J., & Greiner, J. W. (2001) · PubMed · Cited by 125
Self-citation
Clinical Safety of a Viral Vector Based Prostate Cancer Vaccine Strategy
Arlen, P. M., Skarupa, L., Pazdur, M. P., Seetharam, M., Tsang, K. Y., Grosenbach, D. W., Feldman, J. L., Poole, D. J., Litzinger, M. T., Steinberg, S. M., et al. (2007) · The Journal of Urology · doi:10.1016/j.juro.2007.05.117 · Cited by 124
Self-citation
Oncolytic Adenoviruses for the Treatment of Human Cancer: Focus on Translational and Clinical Data
Pesonen, S. A., Kangasniemi, L., & Hemminki, A. (2010) · Molecular Pharmaceutics · doi:10.1021/mp100219n · Cited by 123
Combination Chemotherapy and ALVAC-CEA/B7.1 Vaccine in Patients with Metastatic Colorectal Cancer
Kaufman, H. L., Lenz, H., Marshall, J. L., Singh, D., Garrett, C. R., Cripps, C., Moore, M. J., von Mehren, M., Dalfen, R., Heim, W. J., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0276 · Cited by 122
Analysis of Prognostic Factors Influencing Long‐term Survival After Hepatic Resection for Metastatic Colorectal Cancer
Arru, M., Aldrighetti, L. A., Castoldi, R., Palo, S. D., Orsenigo, E., Stella, M., Pulitanò, C., Gavazzi, F., Ferla, G., Carlo, V. D., et al. (2007) · World Journal of Surgery · doi:10.1007/s00268-007-9285-y · Cited by 120
An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer
Morse, M. A., Hobeika, A. C., Osada, T., Berglund, P., Hubby, B., Negri, S., Niedzwiecki, D., Devi, G. R., Burnett, B. K., Clay, T. M., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci42672 · Cited by 120
Fowlpox virus as a vector in non-avian species
Taylor, J., & PAOLETTI, E. (1988) · Vaccine · doi:10.1016/0264-410x(88)90091-6 · Cited by 118
Selective Induction of High Avidity CTL by Altering the Balance of Signals from APC
Oh, S., Hodge, J. W., Ahlers, J. D., Burke, D. S., Schlom, J., & Berzofsky, J. A. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.5.2523 · Cited by 116
Self-citation
Targeting Antigen in Mature Dendritic Cells for Simultaneous Stimulation of CD4+ and CD8+ T Cells
Bonini, C., Lee, S. P., Riddell, S., & Greenberg, P. D. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.8.5250 · Cited by 114
Vesicular Stomatitis Virus as a Novel Cancer Vaccine Vector to Prime Antitumor Immunity Amenable to Rapid Boosting With Adenovirus
Bridle, B. W., Boudreau, J. E., Lichty, B. D., Brunellière, J., Stephenson, K. B., Koshy, S. T., Bramson, J. L., & Wan, Y. (2009) · Molecular Therapy · doi:10.1038/mt.2009.154 · Cited by 111
Fowlpox Virus Host Range Restriction: Gene Expression, DNA Replication, and Morphogenesis in Nonpermissive Mammalian Cells
Somogyi, P., Frazier, J. A., & Skinner, M. A. (1993) · Virology · doi:10.1006/viro.1993.1608 · Cited by 109
A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings
Oudard, S. M., Rixe, O., Beuselinck, B., Linassier, C., Banu, E., Machiels, J.-P., Baudard, M., Ringeisen, F. P., Velu, T. J., Frère‐Belda, M. L., et al. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0935-9 · Cited by 109
ANTIANDROGEN, VACCINE AND COMBINATION THERAPY IN PATIENTS WITH NONMETASTATIC HORMONE REFRACTORY PROSTATE CANCER
Arlen, P. M., Gulley, J. L., Todd, N., Lieberman, R., Steinberg, S. M., MORIN, S., Bastian, A., Marté, J. L., Tsang, K.-Y., Beetham, P. K., et al. (2005) · The Journal of Urology · doi:10.1097/01.ju.0000165159.33772.5b · Cited by 108
Self-citation
Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity.
Aarts, W. M., Schlom, J., & Hodge, J. W. (2002) · PubMed · Cited by 98
Self-citation
Vaccinia Virus-Related Events and Phenotypic Changes after Infection of Dendritic Cells Derived from Human Monocytes
Drillien, R., Spehner, D., Bohbot, A., & Hanau, D. (2000) · Virology · doi:10.1006/viro.2000.0203 · Cited by 96
Vaccination of Colorectal Cancer Patients with Modified Vaccinia Ankara Encoding the Tumor Antigen 5T4 (TroVax) Given Alongside Chemotherapy Induces Potent Immune Responses
Harrop, R., Drury, N. L., Shingler, W. H., Chikoti, P., Redchenko, I., Carroll, M. W., Kingsman, S. M., Naylor, S., Melcher, A. A., Nicholls, J. P., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0704 · Cited by 90
Vaccination with two different vaccinia recombinant viruses: long-term inhibition of secondary vaccination
Kündig, T. M., Kalberer, C. P., Hengartner, H., & Zinkernagel, R. M. (1993) · Vaccine · doi:10.1016/0264-410x(93)90079-d · Cited by 90
Phase I/II Clinical Trial of a Nonreplicative Vaccinia Virus Expressing Multiple HLA-A0201-Restricted Tumor-Associated Epitopes and Costimulatory Molecules in Metastatic Melanoma Patients
Zajac, P., Oertli, D., Marti, W., Adamina, M., Bolli, M., Güller, U., Noppen, C., Padovan, E., Schultz‐Thater, E., Heberer, M., et al. (2003) · Human Gene Therapy · doi:10.1089/104303403322495016 · Cited by 90
PANVAC™-VF: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma
Madan, R. A., Arlen, P. M., & Gulley, J. L. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.4.543 · Cited by 89
Alphavirus vectors: development and potential therapeutic applications
Schlesinger, S. (2001) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.1.2.177 · Cited by 88
Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses
Harrop, R., Drury, N. L., Shingler, W. H., Chikoti, P., Redchenko, I., Carroll, M. W., Kingsman, S. M., Naylor, S., Griffiths, R., Steven, N. M., et al. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0428-7 · Cited by 85
MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure
Dreicer, R., Stadler, W. M., Ahmann, F. R., Whiteside, T. L., Bizouarne, N., Acres, B., Limacher, J., Squiban, P. J., & Pantuck, A. J. (2008) · Investigational New Drugs · doi:10.1007/s10637-008-9187-3 · Cited by 79
Poxviruses as vaccine vectors
Pastoret, P.-P., & Vanderplasschen, A. (2003) · Comparative Immunology Microbiology and Infectious Diseases · doi:10.1016/s0147-9571(03)00019-5 · Cited by 79
Adjuvant Adenovirus-Mediated Delivery of Herpes Simplex Virus Thymidine Kinase Administration Improves Outcome of Liver Transplantation in Patients with Advanced Hepatocellular Carcinoma
Li, N., Zhou, J., Weng, D., Zhang, C., Li, L., Wang, B., Song, Y., He, Q., Lin, D., Chen, D., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0499 · Cited by 79
Vaccination of Renal Cell Cancer Patients With Modified Vaccinia Ankara Delivering the Tumor Antigen 5T4 (TroVax) Alone or Administered in Combination With Interferon-α (IFN-α)
Amato, R. J., Shingler, W. H., Goonewardena, M., de Belin, J., Naylor, S., Jac, J., Willis, J., Saxena, S., Hernandez-McClain, J., & Harrop, R. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181ace876 · Cited by 78
Local Delivery of Vaccinia Virus Expressing Multiple Costimulatory Molecules for the Treatment of Established Tumors
Kaufman, H. L., Cohen, S., Cheung, K., DeRaffele, G., Mitcham, J., Moroziewicz, D. N., Schlom, J., & Hesdorffer, C. (2006) · Human Gene Therapy · doi:10.1089/hum.2006.17.239 · Cited by 77
Self-citation
Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma
Kaufman, H. L., Taback, B., Sherman, W. H., Kim, D. W., Shingler, W. H., Moroziewicz, D. N., DeRaffele, G., Mitcham, J., Carroll, M. W., Harrop, R., et al. (2009) · Journal of Translational Medicine · doi:10.1186/1479-5876-7-2 · Cited by 76
Samarium lexidronam (153Sm-EDTMP): skeletal radiation for osteoblastic bone metastases and osteosarcoma
Anderson, P. M., & NUÑEZ, R. F. (2007) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.7.11.1517 · Cited by 72
Alphavirus vectors for cancer therapy
Quetglas, J. I., Ruiz-Guillen, M., Aranda, A., Casales, E., Bezunartea, J., & Smerdou, C. (2010) · Virus Research · doi:10.1016/j.virusres.2010.07.027 · Cited by 72
Oncolytic activities of approved mumps and measles vaccines for therapy of ovarian cancer
Myers, R. M., Greiner, S. M., Harvey, M. E., Soeffker, D., Frenzke, M. E., Abraham, K. G., SHAW, A. R., Rozenblatt, S., Federspiel, M. J., Russell, S. J., et al. (2005) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700823 · Cited by 68
Therapeutic Potential of Oncolytic Measles Virus: Promises and Challenges
Galanis, E. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.211 · Cited by 66
Improved Long-Term Outcome of Surgery for Advanced Colorectal Liver Metastases: Reasons and Implications for Management on the Basis of a Severity Score
Andrès, A., Majno, P. E., Morel, P., Rubbia‐Brandt, L., Giostra, E., Gervaz, P., Terraz, S., Allal, A. S., Roth, A. D., & Mentha, G. (2007) · Annals of Surgical Oncology · doi:10.1245/s10434-007-9607-1 · Cited by 62
Vaccination of Renal Cell Cancer Patients with Modified Vaccinia Ankara Delivering Tumor Antigen 5T4 (TroVax) Administered with Interleukin 2: A Phase II Trial
Amato, R. J., Shingler, W. H., Naylor, S., Jac, J., Willis, J., Saxena, S., Hernandez-McClain, J., & Harrop, R. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0668 · Cited by 62
Use of attenuated paramyxoviruses for cancer therapy
Lech, P. J., & Russell, S. J. (2010) · Expert Review of Vaccines · doi:10.1586/erv.10.124 · Cited by 58
Vaccination of Prostate Cancer Patients With Modified Vaccinia Ankara Delivering the Tumor Antigen 5T4 (TroVax)
Amato, R. J., Drury, N. L., Naylor, S., Jac, J., Saxena, S., Cao, A., Hernandez-McClain, J., & Harrop, R. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31817deafd · Cited by 55
Evaluation of Prime/Boost Regimens Using Recombinant Poxvirus/Tyrosinase Vaccines for the Treatment of Patients with Metastatic Melanoma
Lindsey, K. R., Gritz, L. R., Sherry, R. M., Abati, A. D., Fetsch, P. A., Goldfeder, L. C., Gonzales, M. I., Zinnack, K., Rogers-Freezer, L. J., Haworth, L. R., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2061 · Cited by 50
Enhanced viral and tumor immunity with intranodal injection of canary pox viruses expressing the melanoma antigen, gp100
Spaner, D., Astsaturov, I. A., Vogel, T. U., Petrella, T. M., Elias, I., Burdett‐Radoux, S., Verma, S., Iscoe, N., Hamilton, P., & Berinstein, N. L. (2006) · Cancer · doi:10.1002/cncr.21669 · Cited by 48
An MVA-based Vaccine Targeting the Oncofetal Antigen 5T4 in Patients Undergoing Surgical Resection of Colorectal Cancer Liver Metastases
Elkord, E., Dangoor, A., Drury, N. L., Harrop, R., Burt, D. J., Drijfhout, J. W., Hamer, C., Andrews, D., Naylor, S., Sherlock, D., et al. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181876ab3 · Cited by 48
Antigen gene transfer to cultured human dendritic cells using recombinant avipoxvirus vectors
Brown, M. D., Davies, D. H., Skinner, M. A., Bowen, G. P., Hollingsworth, S. J., Mufti, G. J., Arrand, J. R., & Stacey, S. (1999) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700014 · Cited by 43
Vaccination of Patients With Metastatic Renal Cancer With Modified Vaccinia Ankara Encoding the Tumor Antigen 5T4 (TroVax) Given Alongside Interferon-α
Hawkins, R. E., Macdermott, C., Shablak, A., Hamer, C., Thistlethwaite, F. C., Drury, N. L., Chikoti, P., Shingler, W. H., Naylor, S., & Harrop, R. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31819d297e · Cited by 43
Development of Smallpox Vaccine Candidates with Integrated Interleukin-15 That Demonstrate Superior Immunogenicity, Efficacy, and Safety in Mice
Perera, L. P., Waldmann, T. A., Mosca, J. D., Baldwin, N. E., Berzofsky, J. A., & Oh, S. (2007) · Journal of Virology · doi:10.1128/jvi.00538-07 · Cited by 43
Induction of Higher-Avidity Human CTLs by Vector-Mediated Enhanced Costimulation of Antigen-Presenting Cells
Yang, S., Tsang, K.-Y., & Schlom, J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0670 · Cited by 41
Self-citation
A Randomized Phase II Study of Docetaxel Alone or in Combination with PANVAC™-V (Vaccinia) and PANVAC™-F (Fowlpox) in Patients with Metastatic Breast Cancer (NCI 05-C-0229)
Arlen, P. M., Pazdur, M. P., Skarupa, L., Rauckhorst, M., & Gulley, J. L. (2006) · Clinical Breast Cancer · doi:10.3816/cbc.2006.n.032 · Cited by 40
Pox Viral Vaccine Approaches
Arlen, P. M., Kaufman, H. L., & DiPaola, R. S. (2005) · Seminars in Oncology · doi:10.1053/j.seminoncol.2005.09.006 · Cited by 40
Engineered adenovirus serotypes for overcoming anti-vector immunity
Dharmapuri, S., Peruzzi, D., & Aurisicchio, L. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590903187053 · Cited by 38
Oncolytic Herpes Viruses as a Potential Mechanism for Cancer Therapy
Lou, E. (2003) · Acta Oncologica · doi:10.1080/0284186031000518 · Cited by 34
Comparative studies of Avipox-GM-CSF versus recombinant GM-CSF protein as immune adjuvants with different vaccine platforms
Reali, E., Canter, D. J., Zeytin, H. E., Schlom, J., & Greiner, J. W. (2004) · Vaccine · doi:10.1016/j.vaccine.2004.11.060 · Cited by 32
Self-citation
Human B cells that hyperexpress a triad of costimulatory molecules via avipox-vector infection: an alternative source of efficient antigen-presenting cells
Palena, C., Zhu, M., Schlom, J., & Tsang, K.-Y. (2004) · Blood · doi:10.1182/blood-2003-09-3211 · Cited by 29
Self-citation
Advances in viral-vector systemic cytokine gene therapy against cancer
Liu, L., Wang, S., Shan, B., Sang, M., Liu, S., & Wang, G. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.03.041 · Cited by 28
Chronic lymphocytic leukemia (CLL) cells genetically modified to express B7-1, ICAM-1, and LFA-3 confer APC capacity to T cells from CLL patients
Litzinger, M. T., Foon, K. A., Sabzevari, H., Tsang, K.-Y., Schlom, J., & Palena, C. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0611-5 · Cited by 23
Self-citation
Combination Therapy of an Orthotopic Renal Cell Carcinoma Model Using Intratumoral Vector-Mediated Costimulation and Systemic Interleukin-2
Kudo‐Saito, C., Wansley, E. K., Gruys, M. E., Wiltrout, R. H., Schlom, J., & Hodge, J. W. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2398 · Cited by 23
Self-citation
Intratumoral delivery of vector mediated IL-2 in combination with vaccine results in enhanced T cell avidity and anti-tumor activity
Kudo‐Saito, C., Garnett‐Benson, C., Wansley, E. K., Schlom, J., & Hodge, J. W. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0332-1 · Cited by 16
Self-citation
Potential of Alphavirus Vectors in the Treatment of Advanced Solid Tumors
Kelly, B., Fleeton, M. N., & Atkins, G. J. (2007) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/157489207780832432 · Cited by 6

Flagged first, then by citations

Sorted by citations

Dendritic-Cell-Based Therapeutic Cancer Vaccines
Palucka, K., & Banchereau, J. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.004 · Cited by 869
Integrating oncolytic viruses in combination cancer immunotherapy
Bommareddy, P. K., Shettigar, M., & Kaufman, H. L. (2018) · Nature reviews. Immunology · doi:10.1038/s41577-018-0014-6 · Cited by 704
Turning the corner on therapeutic cancer vaccines
Hollingsworth, R. E., & Jansen, K. (2019) · npj Vaccines · doi:10.1038/s41541-019-0103-y · Cited by 689
Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy
Li, Q., Geng, S., Luo, H., Wang, W., Mo, Y.-Q., Luo, Q., Wang, L., Song, G.-B., Sheng, J.-P., & Xu, B. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01953-7 · Cited by 546
Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer
Picard, E., Verschoor, C. P., Grace, W. K., & Pawelec, G. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00369 · Cited by 533

See all 222

Authors: Larocca, C., & Schlom, J.
Affiliations: National Institutes of Health (US)
National Cancer Institute (US)
Corresponding author: Larocca, Cecilia
ORCID: Larocca, Cecilia
Schlom, Jeffrey
Venue: The Cancer Journal
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2011-09
Volume: 17
Issue: 5
Pages: 359-371
ISSN: 1528-9117 (ISSN-L)
DOI: 10.1097/ppo.0b013e3182325e63
PMC: PMC3207353
OpenAlex: W2076096828
Cited by: 222
References: 85
Citations by year: 2026: 7 · 2025: 20 · 2024: 25 · 2023: 21 · 2022: 16 · 2021: 20 · 2020: 16 · 2019: 10 · 2018: 14 · 2017: 9 · 2016: 9 · 2015: 17 · 2014: 17 · 2013: 15 · 2012: 5
FWCI: 1.06
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: The Cancer Journal (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: Howard Hughes Medical Institute
National Institutes of Health
National Cancer Institute (ZIABC010425)
Topics: Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
Keywords: viral vector vaccines, therapeutic cancer vaccines, dendritic cells, antigen presentation, cytotoxic T lymphocytes, neutralizing antibodies, recombinant virus, neoadjuvant and adjuvant therapy, metastatic cancer, combination immunotherapy, clinical trials
MeSH terms: Antigens, Neoplasm, Clinical Trials as Topic, Genetic Vectors, Humans, Male, Prostatic Neoplasms, Viral Vaccines, Viruses, Vaccines, DNA, Cancer Vaccines

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Viral Vector-Based Therapeutic Cancer Vaccines

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks